Baum Charles M
President,Founder,Head of R&D at Mirati Therapeutics, Inc.; Director at ARRAY BIOPHARMA INC
- Sold, on record
- $49.3M
- Dollars the filings state
- Form 4 sales
- 17
- Latest Jan 4, 2023
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- Mirati Therapeutics, Inc.President,Founder,Head of R&D
- ARRAY BIOPHARMA INCDirector
Sales by reason
0
Routine
5
Plan not stated
0
No plan
12
Unusual
Form 4 sales per year, every sale on record.
Sales by company
- Mirati Therapeutics, Inc.467,582 shares
- ARRAY BIOPHARMA INC100,000 shares
Shares sold, every Form 4 sale on record.
Timeline
- Jan 4, 2023Plan not stated
Sold 2.1% of their holdings
$170k3,648 shares at $46.60
- Dec 21, 2022Plan not stated
Sold 5% of their holdings
$367k9,092 shares at $40.42
- Nov 28, 2022Unusual
Sold 35.1% of their holdings
$6.9M69,256 shares at $100.00
- Jan 18, 2022Plan not stated
Sold 1.9% of their holdings
$303k2,517 shares at $120.48
- Jan 4, 2022Plan not stated
Sold 3.9% of their holdings
$608k4,114 shares at $147.75
- Dec 3, 2021Unusual
Sold 29.5% of their holdings
$6.3M47,204 shares at $133.20
- Jun 18, 2021Unusual
Sold 26.2% of their holdings
$6.6M40,000 shares at $165.46
- Jan 6, 2021Plan not stated
Sold 4.9% of their holdings
$949k4,511 shares at $210.39
- Dec 18, 2020Unusual
Sold 28.2% of their holdings
$9.4M40,000 shares at $234.48
- Apr 17, 2020Unusual
Sold 27.3% of their holdings
$3.6M40,000 shares at $90.33
10 of 17
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Jun 22, 2026 | ACRV | Director | AwardedStock Option (Right to Buy) | 20,275 | 20,275 | SEC | ||
| Jun 4, 2026 | Jun 5, 2026 | PMVP | Director | AwardedStock Option (right to buy) | 42,000 | 42,000 | SEC | ||
| May 18, 2026 | May 20, 2026 | ACRV | Director | Awarded | 9,366 | 9,366 | SEC | ||
| Jun 13, 2025 | Jun 17, 2025 | ACRV | Director | AwardedStock Option (Right to Buy) | 20,275 | 20,275 | SEC | ||
| Jun 5, 2025 | Jun 9, 2025 | PMVP | Director | AwardedStock Option (right to buy) | 33,500 | 33,500 | SEC | ||
| Jan 8, 2025 | Jan 8, 2025 | PSTX | Director | Tendered | 78,600 | 0 | SEC | ||
| Jan 8, 2025 | Jan 8, 2025 | PSTX | Director | Returned to the companyStock Option (Right to Buy) | 111,700 | 0 | SEC | ||
| Jun 20, 2024 | Jun 24, 2024 | ACRV | Director | AwardedStock Option (Right to Buy) | 20,275 | 20,275 | SEC | ||
| Jun 17, 2024 | Jun 18, 2024 | PSTX | Director | AwardedStock Option (Right to buy) | 27,350 | 27,350 | SEC | ||
| Jun 17, 2024 | Jun 18, 2024 | PSTX | Director | Awarded | 19,650 | 78,600 | SEC | ||
| Jun 6, 2024 | Jun 10, 2024 | PMVP | Director | AwardedStock Option (right to buy) | 67,500 | 67,500 | SEC | ||
| Jan 23, 2024 | Jan 23, 2024 | Mirati Therapeutics, Inc. | Founder, President, and CEO | Returned to the companyOption to Purchase Common Stock | 718,213 | 0 | SEC | ||
| Jan 23, 2024 | Jan 23, 2024 | Mirati Therapeutics, Inc. | Founder, President, and CEO | Returned to the company | 237,871 | 0 | SEC | ||
| Dec 29, 2023 | Jan 3, 2024 | Mirati Therapeutics, Inc. | Interim CEO | Awarded | 20,425 | $58.75 | $1.2M | 247,700 | SEC |
| Aug 9, 2023 | Aug 10, 2023 | Mirati Therapeutics, Inc. | Interim CEO | Awarded | 54,054 | $37.00 | $2M | 227,275 | SEC |
| Jun 22, 2023 | Jun 28, 2023 | ACRV | Director | AwardedStock Option (Right to Buy) | 32,500 | 32,500 | SEC | ||
| Jun 15, 2023 | Jun 16, 2023 | PSTX | Director | AwardedStock Option (Right to buy) | 27,350 | 27,350 | SEC | ||
| Jun 15, 2023 | Jun 16, 2023 | PSTX | Director | Awarded | 19,650 | 58,950 | SEC | ||
| Jun 8, 2023 | Jun 12, 2023 | PMVP | Director | AwardedStock Option (right to buy) | 21,500 | 21,500 | SEC | ||
| Jan 20, 2023 | Jan 24, 2023 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | AwardedEmployee Stock Option (Right to Buy) | 7,520 | 7,520 | SEC | ||
| Jan 20, 2023 | Jan 24, 2023 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Awarded | 4,444 | 173,221 | SEC | ||
| Jan 4, 2023 | Jan 5, 2023 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Sold | 3,648 | $46.60 | $170k | 168,777 | SEC |
| Dec 21, 2022 | Dec 21, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Sold | 9,092 | $40.42 | $367k | 172,425 | SEC |
| Dec 19, 2022 | Dec 21, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Awarded | 53,618 | 181,517 | SEC | ||
| Nov 28, 2022 | Nov 28, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Sold | 69,256 | $100.00 | $6.9M | 127,899 | SEC |
| Nov 28, 2022 | Nov 28, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Exercised or settledEmployee Stock Option (Right to Buy) | 69,256 | 69,258 | SEC | ||
| Nov 28, 2022 | Nov 28, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Exercised options | 69,256 | $17.41 | $1.2M | 197,155 | SEC |
| Jun 16, 2022 | Jun 16, 2022 | PSTX | Director | AwardedStock Option (Right to Buy) | 57,000 | 57,000 | SEC | ||
| Jun 16, 2022 | Jun 16, 2022 | PSTX | Director | Awarded | 39,300 | 39,300 | SEC | ||
| Jun 2, 2022 | Jun 6, 2022 | PMVP | Director | AwardedStock Option (right to buy) | 19,500 | 19,500 | SEC | ||
| Jan 18, 2022 | Jan 18, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Sold | 2,517 | $120.48 | $303k | 127,899 | SEC |
| Jan 18, 2022 | Jan 18, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Exercised or settledEmployee Stock Option (Right to Buy) | 3,703 | 178,052 | SEC | ||
| Jan 18, 2022 | Jan 18, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Exercised options | 3,703 | $27.00 | $100k | 130,416 | SEC |
| Jan 14, 2022 | Jan 18, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | AwardedEmployee Stock Option (Right to Buy) | 42,325 | 42,325 | SEC | ||
| Jan 14, 2022 | Jan 18, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Awarded | 25,543 | 126,713 | SEC | ||
| Jan 4, 2022 | Jan 6, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Sold | 4,114 | $147.75 | $608k | 101,170 | SEC |
| Dec 16, 2021 | Dec 17, 2021 | Mirati Therapeutics, Inc. | President & CEO | Gift | 7,430 | 105,284 | SEC | ||
| Dec 3, 2021 | Dec 3, 2021 | Mirati Therapeutics, Inc. | President & Head of R&D | Sold | 47,204 | $133.20 | $6.3M | 112,714 | SEC |
| Dec 3, 2021 | Dec 3, 2021 | Mirati Therapeutics, Inc. | President & Head of R&D | Exercised or settledEmployee Stock Option (Right to Buy) | 47,204 | 0 | SEC | ||
| Dec 3, 2021 | Dec 3, 2021 | Mirati Therapeutics, Inc. | President & Head of R&D | Exercised options | 47,204 | $8.49 | $401k | 159,918 | SEC |
| Jun 18, 2021 | Jun 21, 2021 | Mirati Therapeutics, Inc. | President & CEO | Sold | 40,000 | $165.46 | $6.6M | 112,714 | SEC |
| Jun 18, 2021 | Jun 21, 2021 | Mirati Therapeutics, Inc. | President & CEO | Exercised or settledEmployee Stock Option (Right to Buy) | 40,000 | 47,204 | SEC | ||
| Jun 18, 2021 | Jun 21, 2021 | Mirati Therapeutics, Inc. | President & CEO | Exercised options | 40,000 | $8.49 | $340k | 152,714 | SEC |
| Jun 2, 2021 | Jun 9, 2021 | PMVP | Director | AwardedStock Option (right to buy) | 16,333 | 16,333 | SEC | ||
| Apr 5, 2021 | Apr 7, 2021 | PMVP | Director | AwardedStock Option (right to buy) | 32,677 | 32,677 | SEC | ||
| Jan 26, 2021 | Jan 28, 2021 | Mirati Therapeutics, Inc. | President & CEO | Exercised or settledEmployee Stock Option (Right to Buy) | 2,292 | 100,273 | SEC | ||
| Jan 26, 2021 | Jan 28, 2021 | Mirati Therapeutics, Inc. | President & CEO | Exercised options | 2,292 | $5.40 | $12k | 112,714 | SEC |
| Jan 19, 2021 | Jan 20, 2021 | Mirati Therapeutics, Inc. | President & CEO | Exercised or settledEmployee Stock Option (Right to Buy) | 3,245 | 181,755 | SEC | ||
| Jan 19, 2021 | Jan 20, 2021 | Mirati Therapeutics, Inc. | President & CEO | Exercised options | 3,245 | $27.00 | $88k | 110,422 | SEC |
| Jan 15, 2021 | Jan 20, 2021 | Mirati Therapeutics, Inc. | President & CEO | AwardedEmployee Stock Option (Right to Buy) | 30,742 | 30,742 | SEC |
Page 1
Sales and notices (17)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jan 4, 2023 | Jan 5, 2023 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Form 4 sale | 3,648 | $170k | 2.1% | Plan not stated | SEC |
| Dec 21, 2022 | Dec 21, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Form 4 sale | 9,092 | $367k | 5.0% | Plan not stated | SEC |
| Nov 28, 2022 | Nov 28, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Form 4 sale | 69,256 | $6.9M | 35.1% | Unusual | SEC |
| Jan 18, 2022 | Jan 18, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Form 4 sale | 2,517 | $303k | 1.9% | Plan not stated | SEC |
| Jan 4, 2022 | Jan 6, 2022 | Mirati Therapeutics, Inc. | President,Founder,Head of R&D | Form 4 sale | 4,114 | $608k | 3.9% | Plan not stated | SEC |
| Dec 3, 2021 | Dec 3, 2021 | Mirati Therapeutics, Inc. | President & Head of R&D | Form 4 sale | 47,204 | $6.3M | 29.5% | Unusual | SEC |
| Jun 18, 2021 | Jun 21, 2021 | Mirati Therapeutics, Inc. | President & CEO | Form 4 sale | 40,000 | $6.6M | 26.2% | Unusual | SEC |
| Jan 6, 2021 | Jan 8, 2021 | Mirati Therapeutics, Inc. | President & CEO | Form 4 sale | 4,511 | $949k | 4.9% | Plan not stated | SEC |
| Dec 18, 2020 | Dec 21, 2020 | Mirati Therapeutics, Inc. | President & CEO | Form 4 sale | 40,000 | $9.4M | 28.2% | Unusual | SEC |
| Apr 17, 2020 | Apr 20, 2020 | Mirati Therapeutics, Inc. | President & CEO | Form 4 sale | 40,000 | $3.6M | 27.3% | Unusual | SEC |
| Aug 22, 2019 | Aug 23, 2019 | Mirati Therapeutics, Inc. | President & CEO | Form 4 sale | 51,810 | $4.5M | 44.0% | Unusual | SEC |
| Feb 25, 2019 | Feb 27, 2019 | Mirati Therapeutics, Inc. | President & CEO | Form 4 sale | 51,810 | $3.9M | 44.0% | Unusual | SEC |
| Aug 23, 2018 | Aug 24, 2018 | Mirati Therapeutics, Inc. | President & CEO | Form 4 sale | 51,810 | $3M | 50.4% | Unusual | SEC |
| Feb 23, 2018 | Feb 27, 2018 | Mirati Therapeutics, Inc. | President & CEO | Form 4 sale | 51,810 | $1.5M | 50.4% | Unusual | SEC |
| Feb 9, 2018 | Feb 12, 2018 | ARRAY BIOPHARMA INC | Director | Form 4 sale | 50,000 | $845k | 83.3% | Unusual | SEC |
| Mar 28, 2017 | Mar 30, 2017 | ARRAY BIOPHARMA INC | Director | Form 4 sale | 25,000 | $232k | 83.3% | Unusual | SEC |
| May 8, 2015 | May 12, 2015 | ARRAY BIOPHARMA INC | Director | Form 4 sale | 25,000 | $185k | 100.0% | Unusual | SEC |